Stories
Prime pharmacists address AMCP virtual conference as keynote speakers
Catherine Starner, PharmD and Nicole Kjesbo, PharmD discuss the specialty drug pipeline and forecast
April 23, 2021To determine the pipeline and forecast, Starner and Kjesbo consider cost, population/prevalence and management strategies – such as utilization management, prior authorizations and quantity limits. For inclusion on the Watch List, Prime generally focuses on drugs that are submitted to the U.S. Food and Drug Administration (FDA) and have a high anticipated spend based on per member per month (PMPM). Prime forecasts drugs on both medical and pharmacy benefits to help manage total drug spend for its health plan clients.
Starner and Kjesbo focused on pipeline and forecasting for:
While gene therapy approvals have been few and far between, there are more on the horizon. Possible gene therapy reviews include:
- Eladocagene exuparvovec, PTC Therapeutics – aromatic l-amino acid decarboxylase (AADC) deficiency
- SRP-9001, Sarepta Therapeutics – Duchenne muscular dystrophy (DMD)
- AMT-061 (etranacogene dezaparvovec), uniQure – hemophilia B
Prime publishes monthly decisions expected from the FDA and monthly pipelines.
Related news
Stories
September 15, 2023
Prime, Magellan Rx Offer Value Plus to Help States Negotiate Value-Based Contracts for CGTs
Reprinted with permission from MMIT By Angela Maas As more and more high-cost…
Stories
September 15, 2023
Prime Therapeutics ranked No. 3 on Minnesota top private companies list
The Minneapolis/St. Paul Business Journal named Prime Therapeutics (Prime) to its annual list,…
Stories
September 5, 2023
Prime Together Foundation: Helping students achieve their dreams
Since 2002, Achieve Twin Cities has equipped more than 85,000 high school students…